CPT 80362 Targeted Opioid Test Reimbursement

CPT code 80362 represents a targeted toxicology assay that measures or detects one or two opioids or opiate analogs in a specimen. This code captures laboratory work focused on specific narcotic analgesics and is used in clinical contexts where confirmation or quantification of limited opioid exposure is needed. Nationally, opioid toxicology testing remains a critical component of pain management, substance use assessment, and perioperative or forensic evaluation, making clear coding important for clinical documentation and payer adjudication. Key payers in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will learn what CPT code 80362 denotes clinically and operationally, the typical service setting, and which major payers are relevant to coverage and billing discussions. The publication also outlines expected benchmarks, common billing modifiers applicable to lab services (when provided), and the clinical contexts where targeted opioid/opiate assays are commonly ordered. Data not available in the input is noted where applicable, and the content focuses on national implications for coding and clinical use rather than state-level policy.

Billing Code Overview

CPT code 80362 describes a laboratory assay in which a lab analyst measures the amount of or detects the presence of one or two opioids and opiate analogs, a class of narcotic analgesics that depress the central nervous system, in a patient specimen. This service is a targeted toxicology test for specific opioid compounds.

Service type: Targeted opioid/opiate toxicology assay
Typical site of service: Clinical laboratory or other outpatient laboratory facility where specimen collection and analytic testing occur

Clinical Context

A 34-year-old patient on chronic pain management presents for routine urine drug monitoring prior to a scheduled opioid prescription refill. The clinician orders a targeted laboratory test to detect or quantify one or two opioids or opiate analogs in the urine specimen to confirm medication adherence and to screen for non-prescribed opioid use. The specimen is collected at an outpatient collection site and sent to the clinical laboratory. A laboratory analyst performs an appropriate immunoassay or chromatographic method to measure the presence and/or amount of the specified opioids/opiate analogs. Results are reported to the prescribing provider and documented in the electronic health record; where necessary, a confirmatory test (e.g., GC-MS or LC-MS/MS) may follow if initial results are unexpected or require quantitation for clinical decision-making. Typical site of service is an outpatient clinic or hospital outpatient laboratory; the service type is toxicology/opioid drug testing for one or two analytes.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	Use when billing only the professional interpretation/reporting portion of the test separated from technical component
`52`	Reduced services

Taxonomy Code	Specialty	Notes
`207Q00000X`	Anesthesiology	Manages chronic pain clinics where opioid monitoring is routine
`2084P0800X`	Pain Medicine	Pain medicine specialists order and interpret opioid drug tests
`208D00000X`	Emergency Medicine	Orders targeted opioid testing for acute exposures or overdoses
`208000000X`	Pathology & Laboratory Medicine	Laboratory directors and pathologists oversee toxicology testing
`363A00000X`	Nurse Practitioner	Advanced practice clinicians who frequently order urine drug testing

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`Z79.891`	Long term (current) use of opiate analgesic	Indicates chronic opioid therapy where periodic monitoring with targeted opioid testing is standard
`F11.20`	Opioid dependence, uncomplicated	Supports urine opioid testing for monitoring treatment adherence and detecting illicit opioid use
`T40.2X1A`	Poisoning by other opioids, accidental (initial encounter)	Relevant when testing for suspected opioid exposure or overdose
`R78.89`	Other specified abnormal findings of blood chemistry	Used when laboratory testing identifies abnormal toxicology findings needing documentation
`Z51.81`	Encounter for therapeutic drug monitoring	General code supporting the rationale for drug monitoring including opioid assays

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`80305`	Drug test(s), presumptive, any number of drug classes; any number of devices or procedures, capable of being read by direct optical observation only (e.g., dipsticks, cups, cards, cartridges), includes specimen validation when performed, per date of service	Often performed as a point-of-care presumptive screen before or alongside targeted opioid testing to provide rapid initial results
`80306`	Drug test(s), presumptive, any number of drug classes; instrumented analyzer, includes specimen validation when performed, per date of service	Instrumented presumptive screening that may precede a single- or multi-analyte targeted opioid assay
`80307`	Drug test(s), presumptive, any number of drug classes; multiple devices or procedures, per date of service	Used when multiple presumptive methods are used during the same visit prior to targeted testing
`83992`	Therapeutic drug assay, other (e.g., for non-opioid medications)	Used for quantification of non-opioid therapeutic drugs in workflows where multiple medication levels are monitored
`82542`	Assay of opiates; qualitative	Alternative or complementary code for qualitative detection of opiates when more analytes are included
`80365`	Drug test confirmation, any number of drug classes; confirmation by quantitative method (e.g., GC-MS, LC-MS/MS)	Performed after an unexpected or critical result from initial targeted testing for definitive identification and quantitation

OpenPayer

Summary & Overview

CPT 80362: Targeted Opioid and Opiate Analog Toxicology Assay